Method for the generation of a cell composition ventral midbrain patterned dopaminergic progenitor cells

Patent metadata

Field	Value
Publication number	US-11866729-B2
Application number	US-202017011746-A
Country	US
Kind code	B2
Filing date	Sep 3, 2020
Priority date	Sep 13, 2019
Publication date	Jan 9, 2024
Grant date	Jan 9, 2024

Abstract

The present invention discloses an in vitro method for the generation of a cell composition comprising or consisting of ventral midbrain dopaminergic progenitor cells from a cell composition comprising pluripotent and/or multipotent stem cells, the method comprising the steps of A) differentiating said pluripotent and/or multipotent stem cells into ventral dopaminergic progenitor cells, thereby generating a cell composition comprising ventral dopaminergic progenitor cells comprising ventral midbrain dopaminergic progenitor cells and ventral hindbrain dopaminergic progenitor cells, and B) Enriching CD117 positive cells from said cell composition comprising ventral dopaminergic progenitor cells by using an antigen binding molecule specific for the CD117 antigen, thereby generating said cell composition comprising or consisting of ventral midbrain dopaminergic progenitor cells. Cell compositions obtainable by said method are also disclosed.

First claim

What is claimed is:

1. An in vitro method for obtaining a cell population enriched for cells that have a protein expression profile characteristic of ventral midbrain patterned dopaminergic progenitor cells, the method comprising:
a) differentiating a sample of a line of pluripotent and/or multipotent stem cells into a neural cell preparation that contains dopaminergic progenitor cells;
b) dissociating the neural cell preparation into a suspension of individual cells;
c) sorting the individual cells in the suspension using an antigen binding molecule specific for CD117 (c-KIT) into CD117 positive cells and CD117 negative cells; and
d) harvesting the CD117 positive cells from step (c) to obtain said cell population;
wherein at least 70% of the cells in the cell population harvested in step (d) have said protein expression profile characteristic of ventral midbrain patterned dopaminergic progenitor cells.

2. The method according to claim 1 , wherein said method comprises additionally the step of depleting CD171 positive cells from said cell population by using an antigen binding molecule specific for the antigen CD171.

3. The method according to claim 1 , wherein said pluripotent and/or multipotent stun cells are proliferated in a proliferation step before step (a).

4. The method according to claim 1 , wherein said method is performed in a closed system.

5. The method according to claim 4 , wherein said method is an automated method.

6. The method according to claim 1 , wherein said antigen binding molecule specific for the CD117 antigen is an anti-CD117 antibody or antigen-binding fragment thereof.

7. The method according to claim 1 , wherein step (c) is performed by fluorescent activated cell sorting or magnetic cell sorting.

8. The method according to claim 1 , wherein said method comprises additionally the step of depleting pluripotent and/or multipotent stem cells from said CD117 positive cells by using an antigen binding molecule specific for a pluripotent and/or multipotent stem cell surface marker.

9. The method according to claim 8 , wherein the step of depleting pluripotent and/or multipotent stem cells is performed by fluorescent activated cell sorting or magnetic cell sorting.

10. The method according to claim 8 , wherein said antigen binding molecule specific for a pluripotent and/or multipotent stem cell marker is selected from the group consisting of SSEA4, UEA-1, SSEA-3, Tra-1-60, Tra-1-81, SSEA-5, CD90 and CD30.

11. The method according to claim 10 , wherein said antigen binding molecule specific for a pluripotent and/or multipotent stem cell marker is SSEA4.

12. The method according to claim 1 , wherein the ventral midbrain patterned dopaminergic progenitor cells are human or non-human primate cells.

13. The method according to claim 1 , wherein said expression profile includes expression of forkhead box protein A2 (FoxA2).

14. The method according to claim 13 , wherein said expression profile includes lack of expression of octamer-binding transcription factor 4 (Oct3/4).

15. The method according to claim 1 , wherein said expression profile includes expression of FoxA2, orthodenticle homeobox 2 (Otx2) and nuclear receptor related 1 protein (Nurr1).

16. The method according to claim 1 , wherein said line of pluripotent and/or multipotent stem cells is a line of embryonic stem cells (ESC) or a line of induced pluripotent stem cells (iPSC), and step (a) comprises culturing the sample on a cultivation matrix in the presence of differentiation and patterning factors for ventral midbrain patterned cells.

17. An in vitro method composing:
a) obtaining a suspension of single cells from a preparation of dopaminergic progenitor cells differentiated from embryonic stein cells (ESC) or induced pluripotent stem cells (iPSC);
b) specifically sorting cells in the suspension into CD117 positive and CD117 cells; and
c) harvesting the CD117 positive cells from step (b);
wherein at least 80% of the cells harvested in step (c) are positive for FoxA2, Otx2, and Nurr1.

18. The method according to claim 17 , wherein the cells harvested in step (c) is a cell population enriched for ventral midbrain patterned dopaminergic progenitor cells.

19. The method according to claim 17 , which is performed entirely in a closed cell processing system under GMP conditions,
wherein step (b) comprises contacting cells in the suspension with antigen binding molecules specific for CD117 each coupled to a ferromagnetic particle, and retaining cells bearing a ferromagnetic particle in a magnetic field in the closed system while cells not bearing a ferromagnetic particle flow through;
wherein step (c) comprises removing the magnetic field and recovering cells therefrom.

20. The method according to claim 19 , further comprising compounding cells harvested in step (c) with one or more pharmaceutically acceptable carriers, diluents or excipients to form a pharmaceutical composition suitable for administration to a human subject.

21. The method according to claim 19 , wherein 50×10 6 ventral midbrain patterned dopaminergic progenitor cells are retrieved from the closed system at a purity of at least 80%.

22. A plurality of cell populations comprising in separate containers in vitro:
(I) a first cell population enriched for ventral midbrain patterned dopaminergic progenitor cells, obtained by differentiating a first sample of pluripotent or multipotent stem cells, and selecting CD117 (c-Kit) positive cells according to the method of claim 1 ,
wherein said pluripotent or multipotent stem cells are a line of embryonic stem cells (ESC) or induced pluripotent cells (iPSC); and
(II) a second cell population, which is a second sample of the same ESC or iPSC in undifferentiated form, which is capable of being differentiated and enriched to obtain additional ventral midbrain patterned dopaminergic progenitor cells that are autologous to said first cell population.

23. The cell populations of claim 22 , wherein the line is a line of embryonic stem cells (ESC).

24. The cell populations of claim 22 , wherein the line is a line of induced pluripotent stem cells (iPSC).

Assignees

• Miltenyi Biotec Bv & Co Kg

Inventors

• Bosio Andreas
• Smiyakin Andrej

Classifications

• C12N5/0618 Primary

  Cells of the nervous system · CPC title

• A61K35/30

  Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue · CPC title

• G01N33/56966

  Animal cells · CPC title

• C12N2501/998

  Proteins not provided for elsewhere · CPC title

• C12N2506/45

  from artificially induced pluripotent stem cells · CPC title